According to the latest report, Bgi Genomics Co., Ltd. (300676.SZ) announced its Q3 results for 2025. In the first three quarters, the company achieved revenue of RMB 2.674 billion, representing a year-on-year decline of 5.39%. The net loss attributable to shareholders of the listed company was RMB 21.39 million. When excluding non-recurring gains and losses, the net loss attributable to shareholders amounted to RMB 66.76 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments